RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
| 9.68 | |
| 9.75 | |
| - | |
| 9.98 | |
| 9.63 | |
| 6.425-82 | |
| 12 396 K | |
| 1 281 K | |
| 3 707 K | |
| -200 | |
| 3.674 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Biotechnology company Gilead Sciences (NASDAQ:GILD) wasn’t a “Magnificent Seven” company or a darling of the financial markets in 2023. Yet, GILD stock deserves a long-overdue rally in 2024. Gil...
Investigational drugs opaganib and RHB-107 (upamostat) demonstrate distinct synergistic effect when combined individually with remdesivir, significantly improving potency while maintaining cell viabil...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
